- Country: Ukraine
- Summary: Antibody to the Estrogen Receptor, 16 Ml, Nc 024:2023: 57210 - Estrogen/Progesterone Receptor Ivd (In Vitro Diagnostics), Antibodies/ Nc 031:2024: W0102030201 - Tests for the Determination of Estrogen Receptors;...
- UAT Ref No: 132319111
- Deadline: 25 Dec 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: UAH 708744
- Notice Type: Tender
- Document Ref. No.: UA-2025-12-17-013356-a
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Antibody to the Estrogen Receptor, 16 ml, NC 024:2023: 57210 - Estrogen/progesterone receptor IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102030201 - tests for the determination of estrogen receptors; Antibody to the Progesterone Receptor, 7 ml, NK 024:2023: 57210 - Estrogen/progesterone receptor IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102030202 - tests for determining progesterone receptors; Antibody to Her2, 7 ml, NC 024:2023: 57047 - Oncoprotein C-erbB2/Her2/ neu IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102030301 - HER-2/NEU; Antibody to Ki-67, 7 ml, NC 024:2023: 57338 - Antigen Ki67 IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102030399 - Other oncoproteins; Antibody to p53, 7 ml, NK 024:2023: 57515 - Tumor protein p53 IVD (diagnosis in vitro), antibodies/ NC 031:2024: W0102030302 - p53; Antibody to Chromogranin, 7 ml, NC 024:2023: 57052 - Chromogranin A IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102039014 - Chromogranin A; Antibody to Sinatpophysin, 7 ml, NK 024:2023: 57626 - Synaptophysin IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102039009 - tissue protein; Antibody to Cytokeratin mixture, 7 ml, NC 024:2023: 57074 - Pancytokeratin antibody mixture IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102030126 -cytokeratins; Antibody to p161NK4A, 7 ml, NC 024:2023: 57495 - Antigen p16 IVD (in vitro diagnostics), antibodies/ NC 031:2024: W0102030124 - Tumor antigen P16; Antibody to MLH1, 7 ml, NK 024:2023: 57423 - Anti... Type of purchase: goods Classifier and its relevant code: DC 021:2015: 33600000-6 — Pharmaceutical products Grounds for refusal to participate in the procurement procedure Latest version 1. Presence of influence on the customer's decision-making 2. Committing corruption offenses 3. Committing economic offenses 4. Committing criminal offenses 5. Presence of connection of the participant with other participants of the procedure or the customer 6. Violation of a bankruptc...
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINAntibody to the Estrogen Receptor, 16 Ml, Nc 024:2023: 57210 - Estrogen/Progesterone Receptor Ivd (In Vitro Diagnostics), Antibodies/ Nc 031:2024: W0102030201 - Tests for the Determination of Estrogen Receptors;... - Ukraine Tender
The COMMUNAL NON-COMMERCIAL ENTERPRISE "PRYKARPATTIA CLINICAL ONCOLOGY CENTER OF THE IVANO-FRANKIVSK REGIONAL COUNCIL", a Government sector organization in Ukraine, has announced a new tender for Antibody to the Estrogen Receptor, 16 Ml, Nc 024:2023: 57210 - Estrogen/Progesterone Receptor Ivd (In Vitro Diagnostics), Antibodies/ Nc 031:2024: W0102030201 - Tests for the Determination of Estrogen Receptors;.... This tender is published on UkraineTenders under UAT Ref No: 132319111 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-12-25.
The estimated tender value is UAH 708744, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
